{"nctId":"NCT00300430","briefTitle":"Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.","startDateStruct":{"date":"2006-09"},"conditions":["Dyslipidemia","Coronary Heart Disease","Mixed Dyslipidemia"],"count":1911,"armGroups":[{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335 and rosuvastatin calcium"]},{"label":"B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335 and atorvastatin calcium"]},{"label":"C","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ABT-335 and simvastatin"]}],"interventions":[{"name":"ABT-335 and rosuvastatin calcium","otherNames":["ABT-335","TRILIPIX"]},{"name":"ABT-335 and atorvastatin calcium","otherNames":["ABT-335","TRILIPIX"]},{"name":"ABT-335 and simvastatin","otherNames":["ABT-335","TRILIPIX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female subjects who voluntarily sign the informed consent.\n* Subject has successfully completed one of the three ABT-335, rosuvastatin, simvastatin and atorvastatin combination therapy studies.\n\nExclusion Criteria:\n\n* Subject is using or will use investigational medications, except as approved by Abbott.\n* Subject has prematurely discontinued his/her initial therapy one of the prior ABT-335, rosuvastatin, simvastatin and atorvastatin calcium combination therapy studies.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Median Percent Change in Triglycerides From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.0","spread":"27.67"},{"groupId":"OG001","value":"-47.7","spread":"24.62"},{"groupId":"OG002","value":"-56.2","spread":"24.56"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":"23.22"},{"groupId":"OG001","value":"25.1","spread":"25.08"},{"groupId":"OG002","value":"19.4","spread":"20.58"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Direct Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.6","spread":"20.77"},{"groupId":"OG001","value":"-30.2","spread":"21.83"},{"groupId":"OG002","value":"-38.1","spread":"19.09"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 52 in This Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.8","spread":"15.80"},{"groupId":"OG001","value":"-36.6","spread":"16.90"},{"groupId":"OG002","value":"-44.3","spread":"15.72"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Very Low-density Lipoprotein Cholesterol (VLDL-C) From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-56.9","spread":"27.85"},{"groupId":"OG001","value":"-37.7","spread":"63.12"},{"groupId":"OG002","value":"-52.2","spread":"36.54"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Total Cholesterol From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.9","spread":"13.14"},{"groupId":"OG001","value":"-27.5","spread":"14.60"},{"groupId":"OG002","value":"-35.0","spread":"13.01"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.8","spread":"15.40"},{"groupId":"OG001","value":"-35.5","spread":"14.85"},{"groupId":"OG002","value":"-42.9","spread":"14.23"}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Reporting Adverse Events During Combination Therapy, Either in the Preceding Double-blind Studies or in This Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"86","spread":null},{"groupId":"OG002","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Percent Change in High-sensitivity C-reactive Protein (hsCRP) From Baseline to Week 52 of the Open-label Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.87","spread":"265.37"},{"groupId":"OG001","value":"-27.72","spread":"93.62"},{"groupId":"OG002","value":"-39.13","spread":"70.99"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":85},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Back pain","Arthralgia"]}}}